Étude de Patritumab Deruxecan plus pembrolizumab avec d'autres agents anticancéreux chez les participants atteints d'un cancer du sein triple négatif ou hormonal à haut stade à haut risque (MK-1022-010, Herthena-Breast-03)
Une étude de phase 2 randomisée ouverte pour évaluer la sécurité et l'efficacité de Patritumab Deruxecan plus pembrolizumab administré avant ou après la carboplatine / paclitaxel plus pembrolizumab par rapport au pembrolizumab en combinaison avec une chimiothérapie suivie d'une intervention chirurgicale et d'un pembrolizum de haut risque à haut risque Récepteur négatif ou hormonal-bas positif / humain Facteur de croissance épidermique Récepteur-2 Cancer du sein négatif (Herthhena-Breast03)
Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The main goals of this study are to learn:
- About the safety of the study treatments and if people tolerate them
- If people who receive patritumab deruxtecan, pembrolizumab, and chemotherapy before surgery have fewer cancer cells removed during surgery compared to those who receive only pembrolizumab (pembro) and chemotherapy.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Toll Free Number
- Numéro de téléphone: 1-888-577-8839
- E-mail: Trialsites@msd.com
Lieux d'étude
-
-
-
Seoul, Corée du Sud, 03080
- Recrutement
- Seoul National University Hospital ( Site 2400)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +82220720850
-
Seoul, Corée du Sud, 05505
- Recrutement
- Asan Medical Center ( Site 2401)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +82230103217
-
Seoul, Corée du Sud, 03722
- Recrutement
- Severance Hospital, Yonsei University Health System ( Site 2402)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +82222288135
-
-
-
-
-
Córdoba, Espagne, 14004
- Recrutement
- Hospital Universitario Reina Sofia ( Site 1702)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +34 957012408
-
-
Catalonia
-
Badalona, Catalonia, Espagne, 08916
- Recrutement
- Institut Català d'Oncologia (ICO) - Badalona ( Site 1700)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +34934978925
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Espagne, 28027
- Recrutement
- Clinica Universidad de Navarra ( Site 1703)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +34913531920
-
-
-
-
-
Taichung, Taïwan, 407
- Recrutement
- Taichung Veterans General Hospital ( Site 2502)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +886423592525
-
Tainan, Taïwan, 704
- Recrutement
- National Cheng Kung University Hospital ( Site 2503)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +88662353535
-
Taipei, Taïwan, 112
- Recrutement
- Koo Foundation Sun Yat-Sen Cancer Center ( Site 2501)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 886228970011x1686
-
-
-
-
California
-
Santa Monica, California, États-Unis, 90404
- Recrutement
- UCLA Hematology/Oncology - Parkside ( Site 0021)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 424-402-9520
-
-
Illinois
-
Skokie, Illinois, États-Unis, 60077
- Recrutement
- Orchard Healthcare Research Inc. ( Site 0006)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 847-568-9932
-
-
Montana
-
Billings, Montana, États-Unis, 59102
- Recrutement
- Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 406-238-6685
-
-
Oregon
-
Happy Valley, Oregon, États-Unis, 97015
- Recrutement
- Northwest Cancer Specialists, P.C. ( Site 8003)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 360-944-9889
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37203
- Recrutement
- SCRI Oncology Partners ( Site 7000)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 844-482-4812
-
-
Texas
-
Dallas, Texas, États-Unis, 75246
- Recrutement
- Texas Oncology - DFW ( Site 8000)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 214-370-1067
-
Houston, Texas, États-Unis, 77030
- Recrutement
- Houston Methodist Hospital ( Site 0022)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 713-441-9948
-
-
Virginia
-
Norfolk, Virginia, États-Unis, 23502
- Recrutement
- Virginia Oncology Associates (VOA) ( Site 8001)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 844-482-4812
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has locally advanced, non-metastatic (M0), breast cancer, defined as any of the following combined primary tumor (T) and regional lymph node (N) staging per current American Joint Committee on Cancer (AJCC) criteria: cT1c, N1-N2; cT2, N0-N2; cT3, N0-N2; or cT4a-d, N0-N2
- Has centrally confirmed diagnosis of breast cancer that is triple-negative or HR-low+/HER2- breast cancer that will be treated according to the triple-negative breast cancer (TNBC) paradigm
- Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load
- Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 28 days prior to allocation/randomization
- Has left ventricular ejection fraction (LVEF) of ≥50% or ≥ lower limit of normal (LLN) as assessed by echocardiogram (ECHO) or multigate acquisition scan (MUGA) scan
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Has uncontrolled or significant cardiovascular disease before randomization
- Has any history of or evidence of any current leptomeningeal carcinomatosis.
- Has clinically significant corneal disease
- Has human immunodeficiency virus (HIV) infection with a history of Kaposi sarcoma and/or multicentric Castleman disease
- Has evidence of ongoing, uncontrolled, systemic bacterial, fungal, or viral infection
- Has received prior therapy with an anti-programmed death (PD)-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor
- Has received any prior treatment, including radiation, systemic therapy, and/or definitive surgery for currently diagnosed breast cancer
- Has received prior treatment with an anti-human epidermal growth factor receptor 3 (HER3) antibody and/or antibody-drug conjugate (ADC) that consists of an exatecan derivative that is a topoisomerase I inhibitor (e.g., trastuzumab deruxtecan)
- Has metastatic (Stage IV) breast cancer or cN3 nodal involvement
- Has known additional malignancy that is progressing or has required active treatment within the past 5 years
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use, or current or suspected ILD
- Has an active infection requiring systemic therapy
- Has concurrent active HBV and HCV infection
- Has clinically severe respiratory compromise resulting from intercurrent pulmonary illness
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Part 1, A: Pembrolizimab + patritumab deruxtecan → Pembrolizumab + paclitaxel + carboplatin
In Part 1, participants receive neoadjuvant pembrolizumab 200 mg via intravenous (IV) infusion every 3 weeks (Q3W) plus patritumab deruxtecan via IV infusion Q3W for 12 weeks, followed by pembrolizumab 200 mg via IV infusion Q3W plus paclitaxel 80 mg/m^2 via IV infusion every week (QW) and carboplatin AUC1.5 mg/ml/min via IV infusion QW for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer. |
Administered via IV infusion as neoadjuvant treatment
Autres noms:
Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
Autres noms:
Administered via IV infusion as neoadjuvant treatment
Autres noms:
Administered via IV infusion as neoadjuvant treatment
Autres noms:
|
|
Expérimental: Part 2, A: Pembrolizimab + patritumab deruxtecan → Pembrolizumab + paclitaxel + carboplatin
In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion every Q3W plus patritumab deruxtecan (dose to be determined in part 1) IV infusion Q3W for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min IV infusion QW for 12 weeks. At 3-6 weeks after last dose of neoadjuvant treatment, participants undergo surgery for breast cancer. After surgery, participants receive adjuvant pembrolizumab 400 mg IV every 6 weeks (Q6W) for ~30 weeks. Additional adjuvant treatment of physician's choice (TPC) may be given to participants with residual disease. TPC options are olaparib 300 mg oral twice daily (BID) for 1 year (participants with germline BRCA mutation [gBRCAm] only), capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles or doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV Q3W or every 2 weeks (Q2W) and cyclophosphamide 600 mg/m^2 IV Q3W or Q2W for 4 doses. |
Administered via IV infusion as neoadjuvant treatment
Autres noms:
Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
Autres noms:
Administered via IV infusion as neoadjuvant treatment
Autres noms:
Administered via IV infusion as neoadjuvant treatment
Autres noms:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Autres noms:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Autres noms:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Autres noms:
Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2
Autres noms:
Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2
Autres noms:
|
|
Expérimental: Part 2, B: Pembrolizumab + paclitaxel + carboplatin → Pembrolizumab + patritumab deruxtecan
In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min IV infusion QW for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus patritumab deruxtecan (dose to be determined in part 1) via IV infusion Q3W for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will receive adjuvant pembrolizumab 400 mg IV infusion Q6W for ~30 weeks. Additional adjuvant TPC may be administered to participants with residual disease. TPC options include olaparib 300 mg oral BID for 1 year (participants with gBRCAm only), capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles or doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV infusion Q3W or Q2W and cyclophosphamide 600 mg/m^2 IV infusion Q3W or Q2W for 4 doses. |
Administered via IV infusion as neoadjuvant treatment
Autres noms:
Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
Autres noms:
Administered via IV infusion as neoadjuvant treatment
Autres noms:
Administered via IV infusion as neoadjuvant treatment
Autres noms:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Autres noms:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Autres noms:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Autres noms:
Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2
Autres noms:
Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2
Autres noms:
|
|
Comparateur actif: Part 2, C: Pembro + paclitaxel + carboplatin→ Pembro + doxorubicin (or epirubicin) +cyclophosphamide
In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min via IV infusion QW for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV infusion Q3W and cyclophosphamide 600 mg/m^2 IV infusion Q3W for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will receive adjuvant pembrolizumab 400 mg IV infusion Q6W for approximately 30 weeks. Additional adjuvant TPC may be administered to participants with residual disease. TPC options include olaparib 300 mg oral BID for 1 year (participants with gBRCAm only) or capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles. |
Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2
Autres noms:
Administered via IV infusion as neoadjuvant treatment
Autres noms:
Administered via IV infusion as neoadjuvant treatment
Autres noms:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Autres noms:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Autres noms:
Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2
Autres noms:
Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2
Autres noms:
Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Part 1: Number of Participants Experiencing an Adverse Event (AE)
Délai: Up to ~43 weeks
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented for Part 1. |
Up to ~43 weeks
|
|
Part 1: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs)
Délai: Up to 21 days
|
A DLT is defined by the National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE) Version 5.0, assessed by investigator as drug-related: Grade (gr) 3 or 4 nonhematologic toxicity (with exceptions); gr 3 or gr 4 laboratory values (with exceptions); gr 3 or 4 febrile neutropenia; prolonged delay (>2 weeks) in initiating Cycle 2 (cycle length = 3 weeks) due to intervention-related toxicity; any intervention-related toxicity that causes the participant to discontinue intervention during Cycle 1; interstitial lung disease as per investigator; any other gr ≥3 pulmonary toxicity; or gr 5 toxicity. |
Up to 21 days
|
|
Part 1: Number of Participants who Discontinued Study Treatment Due to an AE
Délai: Up to ~30 weeks
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinued study treatment due to an AE will be presented for Part 1. |
Up to ~30 weeks
|
|
Part 2: Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0
Délai: Up to ~30 weeks
|
pCR (ypT0/Tis ypN0) is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy at the time of definitive surgery. |
Up to ~30 weeks
|
|
Part 2: Number of Participants Experiencing an AE
Délai: Up to ~103 weeks
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented for Part 2. |
Up to ~103 weeks
|
|
Part 2: Number of Participants who Discontinued Study Treatment Due to an AE
Délai: Up to ~90 weeks
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinued study treatment due to an AE will be presented for Part 2. |
Up to ~90 weeks
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Part 2: pCR-No Ductal Carcinoma in Situ (DCIS) Rate Using the Definition of ypT0 ypN0
Délai: Up to ~30 weeks
|
pCR-no DCIS (ypT0 ypN0) is defined as the absence of residual invasive and in situ cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy at the time of definitive surgery. |
Up to ~30 weeks
|
|
Part 2: Event-Free Survival (EFS)
Délai: Up to ~100 months
|
EFS is defined as the time from randomization to disease progression that precludes surgery, local or distant recurrence, or death due to any cause, whichever occurs first. |
Up to ~100 months
|
|
Part 2: Overall Survival (OS)
Délai: Up to ~100 months
|
OS is defined as the time from randomization to date of death due to any cause. |
Up to ~100 months
|
|
Part 2: Distant Progression or Distant Recurrence-Free Survival (DPDRFS)
Délai: Up to ~100 months
|
DPDRFS is defined as the time from randomization to first distant progression or distant recurrence event as assessed or death due to any cause, whichever occurs first. |
Up to ~100 months
|
|
Part 2: Residual Cancer Burden (RCB)
Délai: Up to ~30 weeks
|
RCB is defined as residual disease in either the breast or lymph node at the time of surgery. RCB score provides a continuous measurement of the extent of residual cancer. There are four RCB classes: RCB-0 (RCB score 0), RCB-1 (0< RCB score <1.36), RCB-2 (1.36 <RCB score <3.28), and RCB-3 (RCB score >3.28). |
Up to ~30 weeks
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Collaborateurs
Collaborateurs
Les enquêteurs
Les enquêteurs
- Directeur d'études: Medical Director, Merck Sharp & Dohme LLC
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Maladies de la peau
- Maladies du sein
- Maladies de la peau et du tissu conjonctif
- Tumeurs mammaires
- Produits chimiques organiques
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Acides nucléiques, nucléotides et nucléosides
- Hydrocarbures
- Cycloparaffines
- Hydrocarbures, alicyclique
- Hydrocarbures, cyclique
- Terpènes
- Glucides
- Hydrocarbures aromatiques polycycliques
- Hydrocarbures, aromatique
- Composés polycycliques
- Glycosides
- Complexes de coordination
- Taxes
- Cyclodécanes
- Diterpènes
- Désoxycytidine
- Cytidine
- Nucléosides pyrimidine
- Pyrimidines
- Moutards phosphoramides
- Composés de moutarde d'azote
- Composés moutarde
- Hydrocarbures, halogénés
- Phosphoramides
- Composés organophosphores
- Nucléosides
- Uracile
- Pyrimidinones
- Anthracyclines
- Naphtacènes
- Aminoglycosides
- Daunorubicine
- Désoxyribonucléosides
- Fluorouracile
- Capécitabine
- Cyclophosphamide
- Carboplatine
- Doxorubicine
- Paclitaxel
- Épirubicine
- pembrolizumab
- olaparib
- Patritumab Deruxecan
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- 1022-010
- MK-1022-010 (Autre identifiant: MSD)
- U1111-1307-7867 (Identificateur de registre: UTN)
- 2024-514376-40-00 (Identificateur de registre: EU CT)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .